Allosteric Modulation of Group III Metabotropic Glutamate Receptor 4: a Potential Approach to Parkinson’S Disease Treatment

Total Page:16

File Type:pdf, Size:1020Kb

Allosteric Modulation of Group III Metabotropic Glutamate Receptor 4: a Potential Approach to Parkinson’S Disease Treatment Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson’s disease treatment Michael J. Marino*†, David L. Williams, Jr.*, Julie A. O’Brien‡, Ornella Valenti‡, Terrence P. McDonald, Michelle K. Clements, Ruiping Wang, Anthony G. DiLella, J. Fred Hess, Gene G. Kinney, and P. Jeffrey Conn§ Department of Neuroscience, Merck Research Laboratories, West Point, PA 19486 Communicated by Edward M. Scolnick, Merck Research Laboratories, West Point, PA, September 5, 2003 (received for review May 13, 2003) Parkinson’s disease (PD) is a debilitating movement disorder that nergic tone leads to an imbalance between direct inhibition and afflicts >1 million people in North America. Current treatments indirect excitation, such that an excessive basal ganglia output focused on dopamine-replacement strategies ultimately fail in disrupts motor behavior. As indicated on Fig. 1, surgical inter- most patients because of loss of efficacy and severe adverse effects ventions bypass the dopamine system and produce a decrease in that worsen as the disease progresses. The recent success of basal ganglia outflow that results in palliative benefit. Therefore, surgical approaches suggests that a pharmacological intervention a pharmacological intervention that mimics these surgical meth- that bypasses the dopamine system and restores balance in the ods could provide palliative benefit to a larger number of basal ganglia motor circuit may provide an effective treatment patients without the need for invasive surgery. Furthermore, by strategy. We previously identified the metabotropic glutamate bypassing the dopamine system, such a treatment should pro- receptor 4 (mGluR4) as a potential drug target and predicted that duce fewer side effects and may actually slow the disease process selective activation of mGluR4 could provide palliative benefit in by normalizing overactive glutamatergic input to midbrain PD. We now report that N-phenyl-7-(hydroxylimino)cyclopropa[b]- dopamine-containing neurons. chromen-1a-carboxamide (PHCCC) is a selective allosteric potenti- We have been interested in the role of metabotropic glutamate ator of mGluR4. This compound selectively potentiated agonist- receptors (mGluRs) in the function of the basal ganglia and the induced mGluR4 activity in cultured cells expressing this receptor potential that these receptors may provide useful targets for the and did not itself act as an agonist. Furthermore, PHCCC potenti- treatment of PD (for review, see ref. 8). Recent studies indicate -ated the effect of L-(؉)-2-amino-4-phosphonobutyric acid in inhib- that mGluR4 decreases GABAergic transmission at the inhibi iting transmission at the striatopallidal synapse. Modulation of the tory striatopallidal synapse within the basal ganglia (9). In PD, striatopallidal synapse has been proposed as a potential therapeutic increased GABAergic inhibition at this synapse is thought to target for PD, in that it may restore balance in the basal ganglia motor play an important role in motor dysfunction (Fig. 1). Based on circuit. Consistent with this, PHCCC produced a marked reversal of this concept, reduction of ␥-aminobutyric acid (GABA) release reserpine-induced akinesia in rats. The closely related analogue at the striatopallidal synapse by a selective agonist of mGluR4 7-(hydroxylimino)cyclopropachromen-1a-carboxamide ethyl ester, has been suggested as an approach for the treatment of PD. which does not potentiate mGluR4, had no effect in this model. Recently, allosteric modulators of several family C G protein- These results are evidence for in vivo behavioral effects of an coupled receptors (including two of the three groups of mGluRs) allosteric potentiator of mGluRs and suggest that potentiation of have been described, which suggested to us that mGluR4 might mGluR4 may be a useful therapeutic approach to the treatment be amenable to allosteric modulation. We have found that of PD. the group I antagonist N-phenyl-7-(hydroxylimino)cyclopropa- [b]chromen-1a-carboxamide (PHCCC) (10) is a potentiator of arkinson’s disease (PD) is a debilitating neurodegenerative human and rat mGluR4. PHCCC did not itself exhibit mGluR4 Pdisorder that afflicts Ϸ1% of people older than 55 years. The agonist activity, and the closely related analogue 7-(hydroxyl- primary pathology underlying PD is a degeneration of neurons imino)cyclopropa[b]chromen-1a-carboxamide ethyl ester (CPC- in the substantia nigra pars compacta (1). The finding that these COEt) (10) had no mGluR4 potentiator activity, suggesting it neurons are dopaminergic cells that provide a dense innervation might be useful as a control for in vivo studies. Characterization of the striatum (2) led to the development of dopamine- of PHCCC revealed that it does not potentiate or activate any replacement therapies for the treatment of this disease. Drugs other mGluR subtype but acts as an antagonist of some of the such as the dopamine precursor L-dopa and dopamine receptor mGluRs. In brain-slice electrophysiological studies of the rat agonists provide dramatic amelioration of the motor signs of PD striatopallidal synapse, PHCCC was found to potentiate the effect at early stages of the disease. However, prolonged treatment of the mGluR4 agonist L-(ϩ)-2-amino-4-phosphonobutyric acid with these drugs leads to a loss of reliable efficacy and a variety (L-AP4) in inhibiting transmission. Finally, PHCCC was found of motor and cognitive side effects (3). In addition, disagreement still exists as to whether or not L-dopa therapy may actually speed disease progression through increased oxidative damage (for Abbreviations: CPCCOEt, 7-(hydroxylimino)cyclopropa[b]chromen-1a-carboxamide ethyl review, see refs. 4 and 5). Therefore, interest has been renewed ester; GPe, external globus pallidus; L-AP4, L-(ϩ)-2-amino-4-phosphonobutyric acid; PD, Parkinson’s disease; PHCCC, N-phenyl-7-(hydroxylimino)cyclopropa[b]chromen-1a- in the design of therapeutic methods that bypass the dopamine carboxamide; FLIPR, fluorometric imaging plate reader; MPEP, 2-methyl-6-(phenylethy- system. nyl)-pyridine; mGluR, metabotropic glutamate receptor; GABA, ␥-aminobutyric acid. One such method has been suggested by the recent resurgence *M.J.M. and D.L.W. contributed equally to this work. and advances in surgical interventions such as pallidotomy or †To whom correspondence should be addressed at: Department of Neuroscience, Merck deep-brain stimulation. These approaches have led to both Research Laboratories, Merck & Co., Inc., WP46-200, 770 Sumneytown Pike, West Point, PA dramatic palliative benefits for PD patients and an unprece- 19486. E-mail: michael࿝[email protected]. dented refinement of the model of basal ganglia dysfunction ‡J.A.O. and O.V. contributed equally to this work. associated with PD (for review, see refs. 6 and 7). In brief, this §Present address: Department of Pharmacology, Vanderbilt University Medical Center, model suggests that two pathways exist between the striatum and 23rd Avenue South at Pierce, 452-B Preston Research Building, Nashville, TN 37232-6600. the basal ganglia output nuclei. In PD, loss of striatal dopami- © 2003 by The National Academy of Sciences of the USA 13668–13673 ͉ PNAS ͉ November 11, 2003 ͉ vol. 100 ͉ no. 23 www.pnas.org͞cgi͞doi͞10.1073͞pnas.1835724100 Downloaded by guest on October 2, 2021 care and use of animals. Animals were group-housed with access to food and water ad libitum. Brain-Slice Preparation. All experiments were performed on brain slices from 26- to 30-day-old Sprague–Dawley rats (Taconic Farms). Animals were killed by decapitation, and their brains were rapidly removed and submerged in an ice-cold solution containing the following (in millimolar): choline chloride, 126; KCl, 2.5; NaH2PO4, 1.2; MgCl2, 1.3; MgSO4, 8; glucose, 10; and ͞ NaHCO3, 26 equilibrated with 95% O2 5% CO2 (13). The brain was glued to the chuck of a vibrating blade microtome (Leica Microsystems, Nussloch, Germany) and parasagittal slices (300- ␮m-thick) were obtained. Slices were immediately transferred to a 500-ml holding chamber containing artificial cerebrospinal fluid (in millimolar): NaCl, 124; KCl, 2.5; MgSO4, 1.3; NaH2PO4, 1.0; CaCl2, 2; glucose, 20; and NaHCO3, 26; equilibrated with ͞ 95% O2 5% CO2 that was maintained at 32°C. After 20 min at 32°C, the holding chamber was allowed to gradually decrease to room temperature. In all experiments, 5 ␮M glutathione, 500 ␮M pyruvate, and 250 ␮M kynurenic acid were included in the choline chloride buffer and in the holding chamber artificial cerebrospinal fluid. Electrophysiology. Whole-cell patch-clamp recordings were ob- tained as described (9). During recording, brain slices were Fig. 1. Model of the basal ganglia motor circuit. (A) In the normal state, the maintained fully submerged on the stage of a 1-ml brain-slice direct and indirect projections from the striatum to the output nuclei are chamber at 32°C and perfused continuously with equilibrated balanced by striatal dopaminergic tone. (B) In PD, the loss of striatal dopamine artificial cerebrospinal fluid (2–3ml͞min). Neurons were visu- produces an imbalance in the direct and indirect pathways such that an alized by using a differential interference contrast microscope excessive excitation of the output nuclei leads to a large increase in basal ganglia outflow. The sites of action for dopamine-replacement therapy and and an infrared video system. Patch electrodes were pulled from borosilicate glass on a two-stage puller and had resistances in the for surgical interventions
Recommended publications
  • Infiltrating Myeloid Cells Drive Osteosarcoma Progression Via GRM4 Regulation of IL23
    Published OnlineFirst September 16, 2019; DOI: 10.1158/2159-8290.CD-19-0154 RESEARCH BRIEF Infi ltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23 Maya Kansara 1 , 2 , Kristian Thomson 1 , Puiyi Pang 1 , Aurelie Dutour 3 , Lisa Mirabello 4 , Francine Acher5 , Jean-Philippe Pin 6 , Elizabeth G. Demicco 7 , Juming Yan 8 , Michele W.L. Teng 8 , Mark J. Smyth 9 , and David M. Thomas 1 , 2 ABSTRACT The glutamate metabotropic receptor 4 (GRM4 ) locus is linked to susceptibility to human osteosarcoma, through unknown mechanisms. We show that Grm4 − / − gene– targeted mice demonstrate accelerated radiation-induced tumor development to an extent comparable with Rb1 +/ − mice. GRM4 is expressed in myeloid cells, selectively regulating expression of IL23 and the related cytokine IL12. Osteosarcoma-conditioned media induce myeloid cell Il23 expression in a GRM4-dependent fashion, while suppressing the related cytokine Il12 . Both human and mouse osteosarcomas express an increased IL23:IL12 ratio, whereas higher IL23 expression is associated with worse survival in humans. Con- sistent with an oncogenic role, Il23−/− mice are strikingly resistant to osteosarcoma development. Agonists of GRM4 or a neutralizing antibody to IL23 suppressed osteosarcoma growth in mice. These fi ndings identify a novel, druggable myeloid suppressor pathway linking GRM4 to the proinfl ammatory IL23/IL12 axis. SIGNIFICANCE: Few novel systemic therapies targeting osteosarcoma have emerged in the last four decades. Using insights gained from a genome-wide association study and mouse modeling, we show that GRM4 plays a role in driving osteosarcoma via a non–cell-autonomous mechanism regulating IL23, opening new avenues for therapeutic intervention.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Buyers' Guide
    Buyers’ Guide S119 Buyers’ Guide Suppliers’ Contact Details Amersham Biosciences UK Limited The Menarini Group Amersham Place www.menarini.com Little Chalfont Buckinghamshire HP7 9NA Moravek Biochemicals UK 577 Mercury Lane www5.amershambiosciences.com Brea Ca 92821 Avanti Polar Lipids Inc USA 700 Industrial Park Drive www.moravek.com Alabaster AL 35007 Roche Pharmaceuticals USA F. Hoffmann-La Roche Ltd www.avantilipids.com Pharmaceuticals Division Grenzacherstrasse 124 Bachem Bioscience Inc. CH-4070 Basel 3700 Horizon Drive Switzerland King of Prussia Telephone þ 41-61-688 1111 PA 19406 Unites States Telefax þ 41-61-691 9391 www.bachem.org www.roche.com Boehringer Ingelheim Ltd Ellesfield Avenue SIGMA Chemicals/Sigma-Aldrich Bracknell P.O. Box 14508 Berks RG12 8YS St. Louis, MO 63178-9916 UK USA www.boehringer-ingelheim.co.uk www.sigma-aldrich.com Calbiochem Tocris Cookson Ltd. EMD Biosciences, Inc. Northpoint, Fourth Way 10394 Pacific Center Court Avonmouth San Diego Bristol CA 92121 BS11 8TA USA UK www.emdbiosciences.com www.tocris.com S120 Buyers’ Guide Compound Supplier Buyers’ Guide a-methyl-5-HT a-Methyl-5-hydroxytryptamine Tocris ab-meATP ab-methylene-adenosine 5’-triphosphate Sigma-Aldrich bg-meATP bg-methylene-adenosine 5’-triphosphate Sigma-Aldrich (-)-(S)-BAYK8664 (-)-(S)-methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluromethylphenyl)-pyridine-5-carboxylate Sigma-Aldrich, Tocris (+)7-OH-DPAT (+)-7-hydroxy-2-aminopropylaminotetralin Sigma-Aldrich a-dendrotoxin Sigma-Aldrich (RS)PPG (R,S)-4-phosphonophenylglycine Tocris (S)-3,4-DCPG
    [Show full text]
  • Development of Allosteric Modulators of Gpcrs for Treatment of CNS Disorders Hilary Highfield Nickols A, P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neurobiology of Disease 61 (2014) 55–71 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Development of allosteric modulators of GPCRs for treatment of CNS disorders Hilary Highfield Nickols a, P. Jeffrey Conn b,⁎ a Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA b Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA article info abstract Article history: The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy Received 25 July 2013 with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition- Revised 13 September 2013 al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en- Accepted 17 September 2013 dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor Available online 27 September 2013 function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than Keywords: Allosteric modulator orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological CNS modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos- Drug discovery itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that GPCR interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug Metabotropic glutamate receptor selectivity and potentially decreased adverse side effects.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Endogenous Activation of Group-I Metabotropic Glutamate Receptors Is Required for Differentiation and Survival of Cerebellar Purkinje Cells
    The Journal of Neuroscience, October 1, 2001, 21(19):7664–7673 Endogenous Activation of Group-I Metabotropic Glutamate Receptors Is Required for Differentiation and Survival of Cerebellar Purkinje Cells M. V. Catania,1 M. Bellomo,2 V. Di Giorgi-Gerevini,3 G. Seminara,1,4 R. Giuffrida,5 R. Romeo,6 A. De Blasi,7,8 and F. Nicoletti3,8 1Institute for Bioimaging and Pathophysiology of the Central Nervous System (IBFSNC), National Research Council (IBFSNC-CNR), 95123 Catania, Italy, 2Institute of Physiology, University of Messina, 98100 Messina, Italy, 3Department of Human Physiology and Pharmacology, University of Roma La Sapienza, Rome, Italy, Departments of 4Chemical Sciences and 5Physiological Sciences and 6Institute of Anatomy, University of Catania, 95100 Catania, Italy, 7Department of Molecular Pharmacology and Pathology, “Mario Negri Sud” Institute, 66030 S. Maria Imbaro (Chieti), and 8I. N. M. Neuromed, 86077 Pozzilli, Italy We have applied subtype-selective antagonists of metabo- early blockade of mGlu1 receptors induced in rats by local tropic glutamate (mGlu) receptors mGlu1 or mGlu5 [7-(hydroxy- injections of LY367385 (20 nmol/2 ␮l), local injections of mGlu1 imino) cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPC- antisense oligonucleotides (12 nmol/2 ␮l), or systemic admin- COEt) or 2-methyl-6-(phenylethynyl)pyridine (MPEP)] to mixed istration of CPCCOEt (5 mg/kg, s.c.) from postnatal day (P) 3 to rat cerebellar cultures containing both Purkinje and granule P9 reduced the number and dramatically altered the morphol- cells. The action of these two drugs on neuronal survival was ogy of cerebellar Purkinje cells. In contrast, mGlu5 receptor cell specific.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Diamandis Thesis
    !"!#$ CHEMICAL GENETIC INTERROGATION OF NEURAL STEM CELLS: PHENOTYPE AND FUNCTION OF NEUROTRANSMITTER PATHWAYS IN NORMAL AND BRAIN TUMOUR INITIATING NEURAL PRECUSOR CELLS by Phedias Diamandis A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy. Department of Molecular Genetics University of Toronto © Copyright by Phedias Diamandis 2010 Phenotype and Function of Neurotransmitter Pathways in Normal and Brain Tumor Initiating Neural Precursor Cells Phedias Diamandis Doctor of Philosophy Department of Molecular Genetics University of Toronto 2010 &'(!)&*!% The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain brings promise for the treatment of neurological diseases and has yielded new insight into brain cancer. The complete repertoire of signaling pathways that governs these cells however remains largely uncharacterized. This thesis describes how chemical genetic approaches can be used to probe and better define the operational circuitry of the NSC. I describe the development of a small molecule chemical genetic screen of NSCs that uncovered an unappreciated precursor role of a number of neurotransmitter pathways commonly thought to operate primarily in the mature central nervous system (CNS). Given the similarities between stem cells and cancer, I then translated this knowledge to demonstrate that these neurotransmitter regulatory effects are also conserved within cultures of cancer stem cells. I then provide experimental and epidemiologically support for this hypothesis and suggest that neurotransmitter signals may also regulate the expansion of precursor cells that drive tumor growth in the brain. Specifically, I first evaluate the effects of neurochemicals in mouse models of brain tumors. I then outline a retrospective meta-analysis of brain tumor incidence rates in psychiatric patients presumed to be chronically taking neuromodulators similar to those identified in the initial screen.
    [Show full text]
  • ()-PHCCC, a Positive Allosteric Modulator of Mglur4
    Neuropharmacology 45 (2003) 895–906 www.elsevier.com/locate/neuropharm (Ϫ)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection M. Maj a,1, V. Bruno b,1, Z. Dragic a, R. Yamamoto a, G. Battaglia b, W. Inderbitzin a, N. Stoehr a, T. Stein a, F. Gasparini a, I. Vranesic a, R. Kuhn a, F. Nicoletti b,c, P.J. Flor a,∗ a Novartis Institutes for BioMedical Research, Neuroscience Disease Area, WKL-125.6.08, Basel CH-4002, Switzerland b Istituto Neurologico Mediterraneo, Neuromed, Pozzilli, Italy c Department of Human Physiology and Pharmacology, University of Rome, Rome, Italy Received 25 February 2003; received in revised form 27 May 2003; accepted 23 June 2003 Abstract Group-III metabotropic glutamate receptors (mGluR4, -6, -7, and -8) modulate neurotoxicity of excitatory amino acids and beta- amyloid-peptide (bAP), as well as epileptic convulsions, most likely via presynaptic inhibition of glutamatergic neurotransmission. Due to the lack of subtype-selective ligands for group-III receptors, we previously utilized knock-out mice to identify mGluR4 as + the primary receptor mediating neuroprotection of unselective group-III agonists such as L-AP4 or ( )-PPG, whereas mGluR7 is critical for anticonvulsive effects. In a recent effort to find group-III subtype-selective drugs we identified (+/Ϫ)-PHCCC as a positive allosteric modulator for mGluR4. This compound increases agonist potency and markedly enhances maximum efficacy and, at higher concentrations, directly activates mGluR4 with low efficacy. All the activity of (+/Ϫ)-PHCCC resides in the (Ϫ)-enantiomer, which is inactive at mGluR2, -3, -5a, -6, -7b and -8a, but shows partial antagonist activity at mGluR1b (30% maximum antagonist efficacy).
    [Show full text]
  • Genzerthesis.Pdf (828.8Kb)
    Copyright by KathyM.Genzer 2008 COMMITTEE CERTIFICATION OF APPROVED VERSION ThecommitteeforKathyM.Genzercertifiesthatthis is theapprovedversionofthe followingthesis: DOPAMINE-INDUCED SYNAPTIC PLASTICITY IN THE AMYGDALA IN SALINE-AND COCAINE-TREATED ANIMALS UNDERGOING CONDITIONED PLACE PREFERENCE Committee: PatriciaShinnickGallagher,Ph.D. Supervisor GoldaAnneKevetter-Leonard,Ph.D. JosephC.Holt,Ph.D. __________________ Dean,GraduateSchool DOPAMINE-INDUCED SYNAPTIC PLASTICITY IN THE AMYGDALA IN SALINE-AND COCAINE-TREATED ANIMALS UNDERGOING CONDITIONED PLACE PREFERENCE by KathyM.Genzer,B.S. Thesis PresentedtotheFacultyofTheUniversityofTexasGraduate Schoolof Biomedical ScienceatGalveston InPartialFulfillmentoftheRequirements fortheDegreeof MasterofScience ApprovedbytheSupervisoryCommittee PatriciaShinnickGallagher,Ph.D. GoldaAnneKevetter-Leonard,Ph.D. JosephC.Holt,Ph.D. December,2008 Galveston,Texas Keywords:dopamine,PLD,conditionedplace preference ©2008,KathyM.Genzer TheUniversityofTexas MedicalBranch December,2008 Formyparents,whohavealwayssupportedme. ACKNOWLEDGEMENTS Iwanttothankmymentor,Dr.PatriciaShinnick-Gallagherforherwisdom, guidance,andpatience.Shenotonlysupportedmethroughoutmyentire project butalso encouragedmetofollow mytrue passionswhenIchangedmy plansanddecidedto pursuemedicalschool.Icouldnothaveaskedfora bettermentor.Ialsoexpressmy gratitudetomycommitteemembers,Dr.GoldaLeonardandDr.JosephHoltfortheir supportandknowledge. Dr.SebastianPollandtdevotedhis timetohelpingmelearnelectrophysiology,for whichIam grateful.I amalsothankfultoDr.JieLiuwhoaidedmeinmanyexperiments
    [Show full text]
  • Product Update Price List Winter 2014 / Spring 2015 (£)
    Product update Price list winter 2014 / Spring 2015 (£) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg £112 50mg £447 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg £59 50mg £237 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg £70 50mg £282 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg £42 5mg £83 10mg £124 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg £95 50mg £381 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective group 1
    [Show full text]